Scott syndrome is a bleeding disorder associated with an isolated defect in expression of membrane coagulant activity by stimulated platelets. This defect represents a decrease in platelet membrane binding sites for coagulation factors Va and VIIIa, reflecting diminished surface exposure of phosphatidylserine (PS). To gain insight into the cellular and genetic basis for this disorder, B-lymphocytes from a patient with Scott syndrome and from normal donors were immortalized by EBV-transformation, and tested for their capacity to expose plasma membrane PS in response to the Ca2" ionophore, A23187. Upon incubation with A23187, EBVlymphoblasts derived from normal donors consistently induced surface expression of PS in > 70% of all cells, as detected by membrane association of the PS-binding proteins, factor Va or annexin V. PS exposure in these cells was maximal after 5 min, and saturated at < 100 ,uM external free [Ca2"]. By contrast, < 30% of Scott syndrome lymphoblasts exposed PS, and saturation was not observed at > 1 mM external free [Ca2"]. Single-cell clones derived from the Scott lymphoblasts all exhibited a diminished response to A23187 comparable with that of the parental cells, suggesting that all lymphocytes from this patient share this membrane abnormality. Hybridomas prepared by fusion of Scott lymphoblasts with the myeloma cell line UC-LUC showed responses to Ca2+ ionophore comparable to those observed for normal lymphoblasts and for hybridomas prepared by fusion of normal lymphoblasts with UC-LUC. This correction of the Scott abnormality suggests possible complementation of an aberrant gene(s) responsible for this disorder. (J. Clin. Invest. 1994Invest. . 94:2237Invest. -2244
Introduction
The "Scott syndrome" refers to a bleeding disorder associated with an isolated defect in expression of membrane coagulant activity by stimulated platelets (1, 2) . Scott platelets exhibit diminished capacity to promote plasma clotting due to reduced expression of membrane catalytic activity for the tenase (enzyme complex of coagulation factors VIIIaIXa) and prothrombinase (enzyme complex of coagulation factors VaXa) reactions (3, 4) . This defect is now known to represent a decrease in the number of newly exposed membrane binding sites for coagulation factors Va and Vllla by the activated platelets, reflecting diminished surface exposure of phosphatidylserine (PS)' and reduced shedding of coagulant plasma membrane vesicles ("microparticles") from the platelet surface (5, 6) . Although Scott platelets are defective in PS-exposure and microparticle formation in response to either calcium ionophore, complement C5b-9, or agonists such as thrombin and collagen, these platelets exhibit normal agonist-induced secretory and aggregation responses, implying a defect that selectively affects the plasma membrane events that are required for normal expression of platelet coagulant activity (2) . While it has been suggested that Scott platelets contain a deficient or defective membrane component required for the normal coagulant response, the possibility that a plasma-derived inhibitor affects the surface properties of these cells has not been excluded. The erythrocytes and resealed erythrocyte ghosts prepared from this patient have recently been found to exhibit a membrane defect that is similar to that found in the platelets (7) .
The mechanism by which platelet activation initiates movement of phosphatidylserine from inner-to-outer leaflets of the plasma membrane and initiates plasma membrane vesiculation remains unresolved. This response has been shown to depend upon an influx of Ca2' across the platelet plasma membrane, and is most prominent for those agonists that cause large increases in cytosolic [Ca2+] (8) (9) (10) (11) . A similar dependence on Ca2+ is also observed for PS-exposure and expression of coagulant membrane surface by calcium ionophore-treated as well as irreversibly sickled erythrocytes (12) (13) (14) . The activity of several intracellular enzymes, including calmodulin-dependent kinases, calpains, transglutaminase, and phospholipase A2, are known to be regulated by the level of cytosolic Ca2+, and inhibitors of one or more of these enzymes have been reported to affect expression of platelet coagulant activity, although direct causal relationships between enzyme activity and expression of coagulant activity remains unresolved (12, (15) (16) (17) (18) (19) . Recently, it has been reported that Ca2+-induced transbilayer movement of PS depends on the membrane concentration of phosphatidylinositol 4,5-bisphosphate (20) , suggesting direct interaction of this ion with lipid. Nevertheless, biochemical analyses of Scott platelets and erythrocytes have to date failed to reveal a compositional defect of lipid or protein that might account for the impaired responsiveness of these cells to elevated intracellular Ca2+ (2) .
The observation that the plasma membrane defect observed for Scott platelets is also shared by erythrocytes and potentially other hematologic cells suggested the cellular defect might also be identified in a nucleated cell line that could be propagated through in vitro cell culture for genetic analysis. In Fluorescence labeling of proteins. Annexin V and antibody V237 were conjugated with FITC at pH 9.0. The protein to be labeled was dialyzed against sodium MOPS and pH was adjusted to 9.0 by adding 1/10th volume of 1 M sodium carbonate, pH 9.0. To 0.2-0.5 mg of the protein (200-500 ug/ml), 1-2 mg of FITC on Celite was delivered with rapid mixing. After incubation at room temperature for 30-60 min, the reaction was stopped by adding 1 /10th volume of 1 M (NH4)2CO3, pH 7.0. Free dye was removed by gel filtration on Sephadex G-25 (PD-10, Pharmacia Biotech Inc., Piscataway, NJ), followed by exhaustive dialysis against sodium MOPS (V237) or sodium MOPS containing 0.1 mM EDTA (annexin V) in the presence of activated charcoal.
Preparation of AET-treated sheep red blood cells. SRBC were washed twice with HBSS (1,000 g, 10 min, at 18-20°C) , and incubated at 20% hematocrit in a solution of 140 mM AET, pH 9.0, at 37°C for 20 min. The AET-treated SRBC were washed twice with PBS, and then suspended to 4% hematocrit.
EBV-transformed lymphoblasts. EBV-transformed B lymphoblasts were established from a patient with Scott syndrome and from nine normal donors. Briefly, PBMC were separated by Ficoll centrifugation (500 g, 30 min, at 17°C). Separated mononuclear cells were washed twice with serum-free RPMI 1640, and suspended in the standard medium at a concentration of 1 x 107/ml. To 2 ml of PBMC, 2 ml of heat-inactivated FCS and 2 ml of AET-treated SRBC (4% hematocrit) were added. After centrifugation at 200 g for 5 min at 4°C, cells were incubated on ice for 60 min, and then gently suspended. The cells were layered on Ficoll, centrifuged (900 g, 35 min, at 4°C), and the cells in the interface layer were collected, washed with PBS twice, and suspended at 2.5 x 106/ml in serum-free RPMI. The T cell-depleted lymphocytes were transformed by addition of B95-8 EBV transforming virus at a final concentration of 1 transforming U/cell, and incubated for 2 h at 37°C in humidified 5% CO2 with occasional agitation. The cells were recovered by centrifugation, suspended in standard culture medium at 1.25 x 106/ml, and plated in 96-well plates (200 ptl/well).
After 20-40 d of culture, growing cells were harvested and expanded. The EBV-transformed B lymphoblasts were cultured at 37°C in humidified 5% CO2 in standard culture medium. All transformed cell lines were stabilized in culture for two months prior to assay. Three independent transformations of Scott syndrome lymphocytes performed with blood samples obtained from this patient (and matched controls) on separate occasions yielded indistinguishable results.
Cloning of EBV-transformed B lymphoblasts. Cloning was performed by limiting dilution in 96-well plates, with a feeder layer of irradiated human PBMC. Briefly, PBMC from a normal donor were separated by Ficoll centrifugation (500 g, 30 min, at 17°C). Separated PBMC were washed twice with PBS, resuspended in the standard culture medium, and then irradiated with 3,000 rad. Irradiated PBMC were transferred to each well of 96-well microtiter plates (Falcon Labware, Oxnard, CA) at a cell concentration of 1 x 105/ml (100 ,ul/well). After culturing the feeder cells for 2-10 d, feeder cells were aspirated, and 100 IL of the EBV-transformed lymphoblasts were plated in each well (0.3-2.0 cells/well). Approximately half of the medium was changed every 4-7 d. After 2-4 wk of the culture, plates were observed by microscopy for viable clones. Selected clones were expanded in 24-well plates (Falcon Labware), and this procedure was repeated.
Cell fusion. Human B cell hybridoma were prepared by fusion of EBV-transformed lymphoblasts with the hygromycin B-resistant, hypoxanthine guanine phosphoribosyl transferase (HGPRT) -deficient human myeloma cell line, UC-LUC (22) . UC-LUC cells (2 x 107 cells) and EBV-transformed lymphoblasts (4 x I07 cells) were washed twice with serum-free RPMI 1640, and mixed in 50 ml conical tubes. The cells were centrifuged at 200 g for 5 min. After aspirating the supernatant completely, fusion was performed by resuspending the cells in 1 ml of 50% PEG 1,500 at 37°C, added drop-wise over 1 min. After gentle mixing for an additional one minute, the sample was immediately diluted by slow drop-wise addition of serum-free RPMI 1640 at 37°C. The cells were centrifuged at 200 g for 5 min, resuspended in the standard culture medium supplemented with HAT and 400 pg/ml of hygromycin B, and then plated at a cell concentration of 1 x 105/well in 96-well microtiter plates (200 Ml/well). Approximately half of the medium was changed every 4 d. After 2 wk of culture, culture medium was changed to the standard culture medium with HT and 400 Ag/ml of hygromycin B, and then after 3 wk, to the standard culture medium with 400 izg/ml of hygromycin B. Hybridomas were expanded in 24-well plates or T-25 flasks for assay.
Assay of PS exposure by flow cytometry. PS exposure on the B lymphoblast surface was detected by the specific binding of FITCconjugated annexin V (FITC-annexin V) or factor Va, the latter detected with FITC-V237 (19, 21, 24) . Lymphoblasts were washed twice with serum-free RPMI 1640, and suspended at 37°C, in RPMI 1640 supplemented with 0.1% BSA and 1 mM CaCl2 (or, as otherwise indicated) at a concentration of 2.5 x 105 cells/ml. At time = 0, A23187 (1 gUM final concentration) was added from 0.5 mM stock solution in DMSO. In all experiments, identically treated cells receiving DMSO without ionophore served as untreated controls. At times indicated in figure legends, the reaction was stopped by addition of 3 mM EDTA. 50 ,ul of the cells were transferred to tubes containing 5 Ml of bovine factor Va (final concentration, 5 ,ug/ml), and incubated at room temperature for 15 min, after which cells were stained with FITC conjugated V237 Fig. 1 ). Fig. 1 (Fig. 3) . As illustrated by these data, the response of the normal donor lymphoblasts was nearly-maximally expressed within 5 min after addition of ionophore, while the ionophore-induced response of Scott-O cells failed to reach the levels of normal controls, even after 30 min incubation (Fig. 3 A) . The apparent half-maximal induction of the PS-exposed phenotype in A23187-treated lymphoblasts derived from normal donors was observed at approximately 18 j.M extracellular free [Ca2 ], and saturated by 100 1iM Ca2+ (Fig. 3 B) In these experiments, seven independent clonal cell lines derived from Scott-O were analyzed for A23187-induced factor Va binding, and compared to the response of the parental (Scott-0) cell line. The responses of the daughter clones appeared to be normally distributed with respect to that of the parental Scott-0, and all showed markedly diminished responses to A23187 when compared with lymphoblasts derived from normal donors (data not shown). To confirm that the initial cloning resulted in single-cell derived progeny, two of the Scott-0-derived clones, (3E8 and 2C10) were further cloned, and five secondary clones from each were analyzed. All of these secondary clones showed abnormal response to calcium ionophore, characteristic of the Scott-O lymphoblasts (data not shown).
Correction of the abnormal phenotype by somatic cell hybridization. Propagation of the abnormal phenotype of Scott-0 lymphoblasts through multiple cell divisions implied that the basis for this disorder is a gene mutation affecting Ca2 -medi- ated changes in the physical properties of the plasma membrane, a defect that is also presumably shared by the platelet and erythroid progenitor cells of this patient. Unresolved is whether the observed phenotype reflects a mutation that results in a loss of normal function (e.g., a membrane-associated component with diminished affinity for Ca2+), or, whether the phenotype of these cells reflects the over-expression of a cellular component that normally serves to stabilize the plasma membrane. To gain initial insight into the potential for genetic transfer of the Scott trait, hybridoma cell lines were prepared by fusion of the Scott-0 lymphoblasts with the human myeloma cell line, UC- Fig. 5 and Table II) , suggesting a possible "dominance" of the wild-type ("high responder") phenotype that is characteristic of the lymphoblasts derived Previous flow cytometric analysis of the platelets in Scott syndrome suggested that the normal coagulant response to various agonists was attenuated by -60-90% (6), consistent with the estimated two-thirds reduction from normal levels of platelet-catalyzed tenase and prothrombinase activity originally reported for this patient (4 (Table II and Figs. 4 and 5) suggests the possibility for genetic complementation of the membrane defect of the Scott syndrome by expression of the wild type (Ca 2+ -responsive) genome. Although these experiments do not exclude the possibility that the Scott phenotype reflects the over-expression of an inhibitor of the Ca 2+-response in Scott blood cells, the expression of a normal phenotype by all Scott-O/UC-LUC derived hybridomas suggests that the Scott mutation is a recessive loss-of-function mutation that can be corrected through co-expression of the wild-type gene. In addition to providing a stable cellular source for future study of the genetic basis for the cellular defect in Scott syndrome, isolation of clonal cell lines exhibiting a selective defect in Ca2+-initiated PS exposure potentially provides a new tool to undertake identification of those gene(s) responsible for maintaining and collapsing the normal asymmetric distribution of plasma membrane phospholipids.
